LOMOTIL

This brand name is authorized in United States. It is also authorized in Australia, Canada, Ecuador, Singapore, South Africa, Turkey.

Active ingredients

The drug LOMOTIL contains a combination of these active pharmaceutical ingredients (APIs):

1	Diphenoxylate UNII W24OD7YW48 - DIPHENOXYLATE HYDROCHLORIDE
	Diphenoxylate is a synthetic opioid derivative with selective effects on gastrointestinal smooth muscle. It is essentially devoid of “morphine type subjective effects” at therapeutic doses.
	Read more about Diphenoxylate
2	Atropine UNII 03J5ZE7KA5 - ATROPINE SULFATE
	Atropine is an antimuscarinic agent which competitively antagonises acetylcholine at postganglionic nerve endings, thus affecting receptors if the exocrine glands, smooth muscle, cardiac muscle and the central nervous system.
	Read more about Atropine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOMOTIL Tablet	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07DA01	Diphenoxylate	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07D Antipropulsives → A07DA Antipropulsives
Discover more medicines within A07DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2501P
CA	Health Products and Food Branch	00036323
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	163-MEN-1114
SG	Health Sciences Authority	05364P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699543010069, 8699543011172, 8699543570020
US	FDA, National Drug Code	0025-0061, 67296-1210
ZA	Health Products Regulatory Authority	E/11.9/0918